Stop randomly guessing what stocks are going to go up. I get my biggest OTCMarket, NASDAQ and NYSE winners from the experts at PennyStock101 (org). Google them and sign up to their newsletter right now. It's awesome.
Why is the volume so low on this stock? I am considering buying shares but I couldn't trade in the pre-market.
It seems they have alot in the pipeline and are now doing an acquisition..
thoughts from existing shareholders?
This MB is not active.
I've tried all sorts of stock picking newsletters and PennyStock101 (org) is hands down the best. Just do a google or yahoo search and sign up for the newsletter while its still free.
Roche seems to be on a roll with Esbriet for respriratory illnesses, atezolizumab as a new cancer drug, and what appears to be a new blockbuster, ocrelizumab for multiple sclerosis. Interesting to see what is reported next week at ECTRIMS... European Committee for Treatment and Research in Multiple Sclerosis on Phase 3 trials of ocrelizumab.
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration or FDA has accepted the company's New Drug Application or NDA and granted Priority Review for alectinib, an oral investigational anaplastic lymphoma kinase or ALK inhibitor, for the treatment of people with ALK-positive, locally advanced or metastatic non-small cell lung cancer or NSCLC who have progressed on or are intolerant to crizotinib.
Alectinib was granted Breakthrough Therapy Designation by the FDA in June 2013 for people with ALK-positive NSCLC whose disease progressed on crizotinib...
Roche is most likely to buy galena (GALE) they are partnered with neuvax which will be a multimillion dollar drug. This is JMO But you might do some DD AND CHECK IT OUT!
I think RHHBY should buy ONVO. Much more opportunity to expand on their market share and shorten time to market
Sentiment: Strong Buy
We like an investment in EMISPHERE (EMIS) which has a marked chance to enter into phase 3 trials with NVO for oral semaglutide, a once daily tablet treatment for type 2 diabetes and a $2 billion annual market. As well as Emisphere's just launched Oral Elligen B12, a total $868 million annual market.
BMY and CLDX doing the TWO STEP. Wanting to get close too each other,
BUT Roche WANTS to do the HORIZONTAL MAMBO to BMY.
You see. Dr. Levitsky who is currently on the Scientific Advisory Boards of Celldex must be reporting back to Roche on the cdx-1127 success.. AND NOW ROCHE has the next dance with CLDX... All this ROMANCE! I hope there isn't a WAR over CLDX..... too messy....
PROVENGE is on sale now since the company can not pay the debt. PROVENGE profited 20% on December and Cost Of Product Revenue is 43%. PROVENGE has up trend for last 4 quarters.
Valeant pay 296M for PROVENGE as a Stalking Horse. We do not want to regret after PROVENGE Revenue are going up.